SCHEMBL24265686

SCHEMBL24265686

N#Cc1ccc(COc2nn(C3CCNCC3)cc2C#N)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.44
HTR6 P50406 1/20 0.40
ALK Q9UM73 2/20 0.36
MAP4K3 Q8IVH8 3/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
MAP3K8 P41279 1/20 0.36
PRMT5 O14744 1/20 0.36
EGFR P00533 1/20 0.36
GPR119 Q8TDV5 2/20 0.35
KCNH2 Q12809 2/20 0.35
INPPL1 O15357 1/20 0.35
JAK2 O60674 2/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
HTR3A P46098 1/20 0.35
GLP1R P43220 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29574126 1.00 KDM1A (0.44) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL24266549 0.92 HTR6 (0.41) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL24265925 0.89 INPPL1 (0.40) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL29574548 0.89 INPPL1 (0.40) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL24265824 0.89 HTR6 (0.44) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL29573778 0.88 HTR6 (0.46) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL29574663 0.88 HTR6 (0.41) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL24265507 0.88 HTR6 (0.46) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL24266542 0.88 HTR6 (0.41) KDM1AHTR6ALKMAP4K3SLC6A2
SCHEMBL24265441 0.87 MAP4K3 (0.40) KDM1AHTR6ALKMAP4K3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
CN-116507326-A Compounds as GLP-1R agonists 拓臻制药公司 2023-07-28 CN disclosed
WO-2022040600-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2022-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR KDM1A 4184/4885HTR6 246/4885ALK 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.